Detalhe da pesquisa
1.
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
J Neural Transm (Vienna)
; 120(2): 299-307, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22878514
2.
Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Int J Neurosci
; 122(7): 358-62, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22356470
3.
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
J Parkinsons Dis
; 10(2): 543-558, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31929122
4.
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Mov Disord
; 24(9): 1319-24, 2009 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19412946
5.
Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener
; 20(5-6): 421-431, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982356
6.
Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.
Mov Disord Clin Pract
; 4(1): 78-83, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28239615
7.
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet Neurol
; 5(12): 1013-20, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17110281
8.
Long-term evaluation of deep brain stimulation of the thalamus.
J Neurosurg
; 104(4): 506-12, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16619653
9.
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Arch Neurol
; 61(7): 1044-53, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15262734
10.
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.
Arch Neurol
; 60(7): 975-80, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12873854
11.
Long-term studies of dopamine agonists.
Neurology
; 58(4 Suppl 1): S42-50, 2002 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-11909984
12.
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease.
Mov Disord
; 15(3): 485-489, 2000 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28470730
13.
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
Sleep Med
; 4(4): 275-80, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-14592299
14.
Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Clin Neuropharmacol
; 36(4): 122-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23783005
15.
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Neurology
; 61(3): 297-303, 2003 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-12913187
16.
Development and testing of the Parkinson's disease quality of life scale.
Mov Disord
; 18(6): 637-45, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12784266
17.
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Ann Neurol
; 53(5): 624-9, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12730996
18.
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.
Am J Hum Genet
; 72(4): 804-11, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12618962
19.
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.
Hum Mol Genet
; 12(24): 3259-67, 2003 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14570706
20.
Age at onset in two common neurodegenerative diseases is genetically controlled.
Am J Hum Genet
; 70(4): 985-93, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11875758